Industry Policy Committee Materials for employee training on polypharmacy

　　With the aging of the population, physiological changes due to aging and the concomitant use of multiple drugs to treat multiple co-morbidities can easily lead to safety problems. Polypharmacy is the term used to refer to the harmful effects of multiple drug use.
　Pharmaceutical companies that promote the proper use of pharmaceuticals need to understand the problem of polypharmacy and work together with healthcare providers to address it. As a contribution to this effort, the Japan Pharmaceutical Manufacturers Association (JPMA) has released training materials under the supervision of Dr. Masahiro Akishita, the chief of the working group for developing guidelines for the proper use of medicines for the elderly.
　We have updated the training materials (FY2024 version) in accordance with the revision of medical fees in FY2024. Please make use of these materials in your training programs for employees, etc.